Latest Bite Stories

BETHESDA, Md., Sept. 21 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today presented first interim data from a phase 1 dose-escalation clinical study for BiTE antibody MT110, the first T-cell engaging antibody for the treatment of solid tumors. The interim data(1) were presented at the Multidisciplinary Congress of the European Cancer...

BETHESDA, Md., Sept. 17 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and webcast on September 22, 2009 at 7:00 am U.S. Eastern Time to discuss the data from a phase 1 clinical trial with Micromet's anti-EpCAM BiTE antibody MT110, which was presented on September 21, 2009 at the joint 15th...

BETHESDA, Md., Sept. 16 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the UBS Global Life Sciences Conference on September 22, 2009 in New York City. A simultaneous webcast of the event will be available on the company's website at www.micromet-inc.com....

BETHESDA, Md., Sept. 15 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President and CEO, Dr. Christian Itin, will present at the 16th Annual NewsMakers in the Biotech Industry Conference on September 16, 2009 in New York City. A simultaneous webcast of the event will be available on the company's website at...

There may be a way around the harsh skin toxicity associated with a widely used cancer drug, according to a study published online this week in Cancer Biology and Therapy by researchers from City of Hope and the Kimmel Cancer at Jefferson.Cetuximab (Erbitux) is a monoclonal antibody that binds to and inhibits the epidermal growth factor receptor (EGFR). It is widely used to treat colorectal cancer and head and neck cancer. Although cetuximab and other EGFR inhibitors are associated with a...

Children ages 5-9 -- especially boys -- are at greatest risk of dog bites, a U.S. veterinarian says. Dr. Kate Stenske of the University of Kansas says small boys are probably at most risk due to their size and proximity to dogs, their loud noises, fast movements, unintentional provoking and lack of understanding of dogs' body language. Usually, the boys' injuries are usually the most serious from pet bites, Stenske says. Wounds that are most likely to become infected are those on the face...

The sex hormone estrogen plays a critical role in the regulation of growth and the development of cells. It is also crucial for cell-type-specific gene expression in various tissues. Deregulation of this system results in breast and ovarian cancer. Those tumors are successfully treated with drugs such as tamoxifen. Researchers suggest that this drug inhibits tumor growth by blocking the estrogen receptors of the tumor cells. However, up to now it has been unclear what effect this...

BETHESDA, Md., Aug. 6 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced its financial results for the second quarter and six months ended June 30, 2009. In the second quarter of 2009, Micromet achieved a number of significant milestones illustrating its continued progress in the clinic and in corporate development. The milestones...

Any animal can bite, even cute, friendly ones that people have known for years, a U.S. veterinarian warns. If they are put in a new and threatening situation, they may bite, Dr. Kate Stenske of the University of Kansas in Manhattan said in a statement. To prevent bites from pets, it helps to recognize subtle signs of fear, nervousness or aggression in an animal, Stenske says. When it comes to strange dogs, Stenske says, it's best to never approach them, but if a strange dog approaches,...

BETHESDA, Md., Aug. 3 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it has received Orphan Drug Designation from the European Medicines Agency (EMEA) for BiTE antibody blinatumomab (MT103) for acute lymphoblastic leukemia (ALL). Blinatumomab is a novel therapeutic antibody that activates a patient's T cells to seek out and...